January 2009 - Volume 3, Issue 1

Effect of ß- Thalassemia on Some Biochemical Parameters


Nazdar Ezzaddin Rasheed1, Salar Adnan Ahmed2

  1. MBChB, MSc, Assistant Lecturer - Pediatric Department/ College of Medicine/ Hawler Medical University
  2. MSc. in Clinical Biochemistry-Dept. of Clinical Biochemistry / College of Medicine / Hawler Medical University

ABSTRACT

Background and objectives: Thalassemia or hemoglobinopathy is a hereditary disease caused by defective globin synthesis resulting in abnormal as well as decreased quantity of globin chains. Ineffective erythropoiesis, hemolysis, and increased red blood cell turnover.

The present study deals with the effects of ß-thalassemia on the following serum biochemical parameters (sodium, potassium, calcium, phosphate and uric acid).

Material and method: A prospective study was carried out from September 2004 to March 2005 by collaboration between clinical biochemistry and pediatric departments in College of Medicine, Hawler Medical University on thirty patients with ß-thalassemia in comparison with thirty normal subjects.

Results: The results showed that there was a significant difference (P< 0.05) in the level of serum Potassium, Calcium, Uric acid and hemoglobin while the differences in sodium and phosphate were not significant.

Conclusion: Based on findings of the present study it can be concluded that ß-thalassemia causes multiple abnormalities in biochemical parameters.

 

INTRODUCTION

The thalassemia syndrome is a group of metabolic inherited disorders(1) characterized by microcytic hypochromic red blood cells. The homozygous state, thalassemia major results in a severe anemia and often death before puberty. The heterozygous state, thalassemia minor is less severe and may be asymptomatic with little or no anemia(2,3)

The word thalassemia comes from the Greek "thalassa", sea referring to thr Mediterranean and "haima", blood which means blood disease of the sea(3,4,5). The first description of severe thalassemia as a unique disorder was described in 1925 by a Detroit pediatrician "Thomas Cooley" who described a severe type of anemia in children of Italian origin which was later named after him(3).

Thalassemia represents the most common single gene disorder causing a major public health problem(6)

It is widely distributed through the Mediterranean, Middle East, India, southeast Asia and Africa(5). Iraq is one of the countries in which 6-10% of the population have hemoglobinopathy of which thalassemia is a major part(7)

The underlying abnormality in the thalassemia syndromes is thought to be absence or reduction in production of hemoglobin(2)

There are 2 types of thalassemia - alpha and beta depending on which globin chain is affected by genetic mutation or deletion(8).

The disease is called beta thalassemia when ß chain production is decreased relative to alpha chain production and alpha thalassemia when a chain production is decreased relative to ß(2, 6).

Over the last 3 decades the development of regular transfusion therapy and iron chelating has dramatically improved the quality of life however in the developing world, poor availability of proper medical care, and safe and adequate red blood cell transfusion, together with poor compliance to chelation therapy remains a major obstacle. Despite the increased life expectancy thalassemia complications keep arising especially iron overload related complications as well as toxicities of iron chelator(9) which may result in metabolic and endocrine abnormalities like hypogonadism, diabetes mellitus, hypothyroidism, hypo-parathyroidism and zinc and copper deficiency(10,11,12).

Precipitation of alpha globin chains in the thalassemia RBC may interfere with normal membrane function leading to increased calcium content which is more pronounced in splenectomy patients correlates with the degree of anemia(11).

 

METHODS AND MATERIALS

1- Subjects
This study was conducted on 60 individuals all under 17 years, thirty 30 of whom were patients with ß-thalassemia and the other thirty 30 were healthy controls.

ß-Thalassemic patients in Erbil were all registered in a pediatric hospital thalassemic unit to receive treatment. The diagnosis of thalassemia was based on hematological criteria (peripheral blood evaluation and hemoglobin electrophoresis of the patients from early years of life. The mean ± S.E of age was 11.93±1.1 years and the range 1-16 years. While the healthy individuals mean ±S.E of age was 12.2±1.1 years and the range 1-17 years - see Table 1

2-Blood sample collection:
Three to five millilitres of venous blood was drawn from ß-thalassemic patients and healthy individuals. Collected blood was left standing at room temperature until it clotted, then the sample centrifuged at 300 rpm for 10 minutes for removal of serum from suspended cells. Then the serum was tested for sodium, potassium, calcium, phosphorous and uric acid determination.

Table (1): The host information of  ß-thalassemiac patients and reference group
Groups Total Number Numbers Age (years)
Male Female Mean ±S.E Range
Group I 30 14 16 12.2±1.1 1-17
Group II 30 12 18 11.93±1.1 1-16


 


3-Instruments
1- Spectrophotometer (Spectronic 21)
2- Centrifuge type Labofuge 200
3- Computer for data analysis
4- Flame photometer (Jenway)

4-Method
Sodium and potassium in Serum was measured by an instrument called a Flame photometer according to Varly(13) method as follows:

Principle of operation (Flame photometry):-
Flame photometry relies upon the fact that the compounds of the alkaline earth metals can be thermally dissociated in a flame and that some atoms produced will be further excited to a high energy level. When the atoms return to ground state they emit radiation which lies mainly in the visible region of the spectrum (each element emits radiation at a wave length specific to that element(13) while routine biochemical tests were done in serum for phosphorous determination according to Gomorri methods(14).

Serum uric acid and calcium was determined for both groups by an enzymatic colorimetry method by using ready made kits Biomerieux Sa. (France) according to the method of (Barhand and Coms) respectively(15, 16).

5-Statistical evaluation
Statistical analyses were carried out by using some statistical measurements. Biochemical values were presented as the mean±S.EM and range. All analyses for difference between the two independent groups were performed by Student's t tests, with a level of significance assigned at 0.05. Values less than 0.05 (P<0.05) were considered to indicate statistical significance(17).

Table (2): Biochemical parameters of the studied group
Parameters Unit Normal Patient Satistical Evaluation
Range Mean±S.E Range Mean±S.E
Potassium mmol/L 3.2-6.4 4.8±0.1 3.6-7.5 5.3±0.2 P<0.05
Sodium mmol/L 122-150 139±1.5 122-159 141±1.6 N.S
Calcium mg/dl 8.7-15 11.3±0.3 2.4-6.6 4.6±0.2 P<0.01
Phosphate mg/dl 1.1-8 4.8±0.3 3.5-9.4 5.6±0.3 N.S
Uric acid mg/dl 2.8-8.6 4.6±0.2 3.8-91 5.9±0.3 P<0.01
Hb g/dl 13.9-8 11±0.1 8.4-4.8 7.5±0.2 P<0.01
Age years 1-17 12.2±1.1 1-16 11.93±1.1 N.S

 

 

 

 

 


 

RESULTS

Group I (Healthy individuals):
The mean±S.E for serum Potassium gave values of 4.8±0.1 mmol/L and a range of 3.2-6.4 mmol/L. The mean±S.E for serum Sodium was 139±1.5 mmol/L and the range was 122-150 mmol/L. The mean±S.E values for Calcium, Phosphorous and Uric acid were 11.3±0.3, 4.8±0.3 and 4.6±0.2 mg/dl respectively, with the range of 8.7-15, 1.1-8 and 2.8-8.6 mg/dl respectively as shown in Table 1.

Group II (ß-thalassemic patients):
The mean for serum Potassium gave values of 5.3±0.2 mmol/L and a range of 3.6-7.5. The mean for serum Sodium was 141±1.6 and the range was 122-159 mmol/L. The mean value for Calcium, Phosphorous and Uric acid were 46±0.2, 5.6±0.3 and 5.9±0.3 mg/dl respectively, with the range of 2.4-6.6, 3.5-9.4 and 3.8-91 mg/dl respectively as shown in Table 2.

In comparison between healthy individuals and ß-thalassemiac individuals, it was showed significant differences in serum Potassium, Calcium, Uric acid and Hb while serum phosphorous and sodium showed no significance - see Table 2 Figure 1 and Figure2.

Figure(1): Serum sodium and potassium in normal and ß-thalassemic patients

 

Figure(2): Serum total Calcium, Phosphate and Uric acid in normal and ß- thalassemic patients

 

DISCUSSION

The goal of the present study was to understand the effects of ß-thalassemia on certain serum biochemical parameters (Sodium, potassium, calcium, phosphate and uric acid).

The aim of transfusion is to maintain a hemoglobin level that inhibits ineffective erythropoiesis, marrow expansion and allow normal growth. The hemoglobin should be maintained between 10-14 gm/dl with pre-transfusion hemoglobin of 10-11 gm/dl. Most patients in the present study were suboptimally blood-transfused thalassemics. They had significant anemia of 7.5±0.2g/dl which resulted in growth retardation, delayed puberty, and retarded bone age. These findings were in agreement with the previous studies(1,18,19).

The results obtained in this study as noted earlier showed that the mean value [Mean±S.E.] of serum Potassium for ß-thalassemiac patients was 5.3±0.2 mmol/L. The mean value for Uric acid was 5.9±0.3 mg/dl. The values were significantly higher in ß-thalassemiac patients compared with the control group (p<0.05) which is in accordance with Kostas et al(20).

Increased hemolysis and/or red cell turnover might be blamed for the elevated serum potassium and uric acid levels. Highest normal value of uric acid in the beta-thalassemic patients, despite the increased red cell turnover could be due to the increased excretion of uric acid, evidenced by the high fractional excretion in uric acid, which may be the result of the supra normal proximal tubular function(21).

Aldosterone is a mineralo-corticoid which acts on P cells of the distal tubule and causes Na + reabsorption in exchange for K+ or H+ secretion. This defect in potassium secretion is not clinically apparent under normal circumstances, though hyperkalemia is likely to manifest with mild degrees of renal impairment(22). This might explain the slight elevation of potassium to upper normal range in our study.

Furthermore, there was also a statistically significant difference in serum calcium between the control grouip and ß-thalassemiac patients. The same observation for calcium level was also reported by Saka et al(23).

On the other hand a non-significant increase in the mean levels of serum phosphorous was found in patients with ß-thalassemia compared to the control group, This finding is similar to that found by Kostas et al(20).

The ß-thalassemia major results in severe anemia, which needs regular blood transfusion. The combination of transfusion and chelating therapy has dramatically extended the life expectancy of thalassemic patients(22,23). On the other hand, frequent blood transfusion in turn can lead to iron overload(24,25).

Hypocalcaemia is a well known complication of iron overload(26). Iron overload occurs either from the transfusion of red blood cells or because there is increased absorption of iron from the digestive tract. Both of these occur in thalassemia. Iron overload also causes pituitary damage with hypogonadism, endocrine complication, hypothyroidism and hypoparathyroidism is also seen(27).
Parathyroid hormone which is secreted by the parathyroid gland mobilizes calcium from bone(27,28).

A study done by Desanctis 1995 showed that hypocalcemia due to hypoparathyroidism is recognized as a later complication (age 16 year and above) although in our study hypocalcemia was observed in a very younger age. This could be attributed to poor patient compliance due to poor education about the disease. An iron chelating agent with its pump is not always available, and communications between the thalassaemic centers and the patients are not always easy.


CONCLUSION AND RECOMMENDATION
  1. Pre transfusion Hb value was suboptimal so more effort is required to educate families on better compliance and more support is required for donation of blood to thalassemic centers.

  2. Hypocalcaemia is found in early age and might be due to unavailability of a dysferoxamine pump or poor compliance.
  3. Serum potassium was found to be in the upper normal range and might be due to mild renal impairment, so future study should be done on the effect of thalassemia on renal function.
  4. Screening for thalassemia must be included and other tests pre marriage are required since thalassemia is very common in the north of Iraq.
  5. More governmental & non-governmental support is required focusing on availability of therapy, discovery of new cases, as well asl education of families about thalassemia and it's effect on growth.


REFERENCES

  1. Zakaria M Al-Hawsawi, Ghousia A Ismail, Hanan A. Al-Harbi, Zaki R Al-Sobhi. B-thalassemia major, Saudi Medical Journal; 2003, 24 (9): 1027-1029
  2. Robert B.Gunn ,David N.Silvers and Wendell F. Rosse Potassium permeability in ß - Thalassemia minor red blood cells ,Clinical investigation, 1973; 51:1045-49
  3. Mangalani M, Lokeshwar M.R, Banerjee R. Bone Histomorphometry in Children and Adolescents with ß-Thalassemia Disease: Iron-Associated Focal Osteomalacia, The Journal of Clinical Endocrinology & Metabolism; 2003; 88(8) 3966-3972
  4. Cooley TB, Lee P A series of cases of splenomegaly in children with anemia and peculiar changes Trans Am Pediatr Soc, 1975; 37:29-30
  5. David G. Nathan. Prospective on Thalassemia PEDIATRICS 1998; Vol.102 No. 1 Supplement July, PP 281-283
  6. Susanne R. Christoph B. Gunter H..Oral isobutyramide reduces transfusion requirements in some patients with ß-thalassemia 2000, 96(10): 3357-63
  7. David P. Steensma, James D. Hoyer and Virgil F. Fairbanks: Hereditary red blood cell disorders in Middle Eastern patients. Mayo Clin Proc.2001; 76:285-293
  8. Antia J. Cattin, Thalasssemia : the facts and the controversies, Pediatr Nurs . 2003; 29(6): 447-451. www.medscape .com/viewarticle /466838
  9. M.B. Agarwal Advances in Management of Thalassemia, indian pediatrics; 2004; 41:989-992
  10. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B: High prevalence of low bone mass in thalassaemia major .B J Haemat 1998, 103:911-915
  11. Shalev O, Mogilner S and Shiner E, Impaired erythrocyte calcium homeostasis in beta-thalassemia. Blood; 1984; 64(2):564-6
  12. Alireza Abdollah Shamshirsaz , Mir Reza Bekheirnia, Mohammad Kamgar1, Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran .BMC Endocrine Disorders 2003, 3:4
  13. Varly H. Practical clinical biochemistry; Willian, Heineman Medical Books, London, 5th ed 1980, Volume(1) p.771
  14. Gomorri G. Determination of serum phosphorous. J. Lab. Clin. Med, 1942, 27:955
  15. Corns C and Ludman C Determination of Calcium. Ann .Clin. Biochemistry 1987; 24:345
  16. Barham and Trinder. Estimation of serum uric acid. Analyst. 1972; 97:142.
  17. Danial ww. Biostatistics : a foundation for analysis health science 1983; 3rd. John Wiley and Sons, USA
  18. Pat Mahachoklertwattana, Vorachai Sirikulchayanonta, Ampaiwan Chuansumrit. Bone Histomorphometry in Children and Adolescents with ß-Thalassemia Disease: Iron-Associated Focal Osteomalacia. The Journal of Clinical Endocrinology & Metabolism. 2003; 88(8) 3966-3972
  19. Saka N, Sukur M, Bundak R, Anak S, Neyzi O, Gedikoglu G Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab; 1995;8:181-186
  20. Kostas P. Katopodis, Moses S. Elisaf, Haralampos A. Pappas. Renal abnormalities in patients with sickle cell-beta thalassemia. J. of. Nephrology ;1997;Vol.10(3):163-167
  21. Soliman AT, El Banna N, Abdel Fattah M, ElZalabani MM, Ansari BM
    Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal dataMetabolism. 1998 May; 47 (5) :541-8.
  22. Saka N, Sukur M, Bundak R, Anak S, Neyzi O, gedikoglu G: Growth and puberty in thalassemia major.J Pediatr Endocrinol Metab, 1995; 8:181-186
  23. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassemia major. BMJ , 1982; 284:1081-1084
  24. Jensen CE, et al . High prevalence of low bone mass in thalassaemia major.B J Haemat, 1998; 103:911-915
  25. Vullo C, et al. Endocrine abnormalities in thalassemia.
    Ann NY Acad Sci , 1990; 612:293-310
  26. Ali hasan dhary aljumaily, Shaimaa khider. Prevalence of hypocalcemia among thalassemic patients registered in IBN, 2005,
    www.ajman.ac.ae/arabmed/abstracts/poster_session3.pdf
  27. Gentner J.: Disorder of calcium and phosphorous homeostasis. Pediatric Clin North Am.1990; 37:1441-1466
  28. Ganong W.S; Review of medical physiology. 2002; 10th e

Disclaimer
l © Copyright 2007 medi+WORLD International Pty. Ltd.